Janssen-Visible Cohort A Week 16 Topline Results Achieve Co-Primary Endpoints, Showing Established Efficacy, Safety Profile Of Tremfya Across Skin Tones
Portfolio Pulse from Benzinga Newsdesk
Janssen, a pharmaceutical company owned by Johnson & Johnson (JNJ), has announced that its Week 16 topline results for the Visible Cohort A study have achieved co-primary endpoints. The study shows the established efficacy and safety profile of Tremfya across different skin tones.
October 20, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from Janssen's study could potentially boost the sales of Tremfya, which would be beneficial for Johnson & Johnson's revenues.
The news directly pertains to Johnson & Johnson as Janssen is a subsidiary of the company. The positive results from the study could lead to increased sales of Tremfya, which would increase JNJ's revenues. Therefore, the news is likely to have a positive impact on JNJ's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100